Royalty Pharma (RPRX) Common Equity (2019 - 2026)
Royalty Pharma (RPRX) posted Common Equity of $9.9 billion for Q1 2026, up 2.28% sequentially from $9.7 billion in Q4 2025, and up 1.63% YoY from $9.8 billion in Q1 2025.
Royalty Pharma (RPRX) Common Equity (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Common Equity for 8 years, with the latest figure at $9.9 billion in Q1 2026.
- Quarterly Common Equity rose 1.63% year-over-year to $9.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 billion (up 1.63% YoY) and the FY2025 annual result came in at $9.7 billion, down 6.07% from the prior year.
- Common Equity grew to $9.9 billion in Q1 2026 per RPRX's latest filing, from $9.7 billion in the prior quarter.
- Over five years, Common Equity peaked at $10.4 billion in Q3 2022 and troughed at $9.5 billion in Q2 2025.
- A 5-year average of $9.9 billion and a median of $9.8 billion in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity decreased 7.98% in 2023, then advanced 7.03% in 2024.
- Over 5 years, Common Equity stood at $9.5 billion in 2022, then climbed by 5.87% to $10.1 billion in 2023, then climbed by 2.56% to $10.3 billion in 2024, then slipped by 6.07% to $9.7 billion in 2025, then rose by 2.28% to $9.9 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $9.9 billion, $9.7 billion, and $9.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 4.92 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.79 Bn |
| Mar 31, 2026 | 9.94 Bn |
| Dec 31, 2025 | 9.71 Bn |
| Sep 30, 2025 | 9.62 Bn |
| Jun 30, 2025 | 9.50 Bn |
| Mar 31, 2025 | 9.78 Bn |
| Dec 31, 2024 | 10.34 Bn |
| Sep 30, 2024 | 10.26 Bn |
| Jun 30, 2024 | 9.75 Bn |
| Mar 31, 2024 | 9.86 Bn |
| Dec 31, 2023 | 10.08 Bn |
| Sep 30, 2023 | 9.59 Bn |
| Jun 30, 2023 | 9.81 Bn |
| Mar 31, 2023 | 9.82 Bn |
| Dec 31, 2022 | 9.53 Bn |
| Sep 30, 2022 | 10.42 Bn |
| Jun 30, 2022 | 10.41 Bn |
| Mar 31, 2022 | 10.14 Bn |
| Dec 31, 2021 | 10.25 Bn |
| Sep 30, 2021 | 10.39 Bn |